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and Moses S. S. Chow, PharmD, FCP
There are limited data on the effects of Glass lB and IC antiarrhythmic drug combination
for the treatment of ventricular tachycardia. The present study evaluated this combina-
tion in 12 patients who had sustained ventricular tachycardia (SuVT) during pro-
grammed electrical stimulation (PES) and failed IC antiarrhythmic therapy. Following
combination of lidocaine and a IC agent (7 with encainide and 5 with jlecainide), two had
no inducible ventricular tachycardia (VT) and one had nonsustained VT (NSVT). In seven
of nine patients who stillhad SuVT, the mean VT cycle length increased 40 ± 25 msec
post combination compared to IC antiarrhythmic therapy. Seven patients who had a
favorable response to the initialcombination (<10 beats of NSVT, or 10 beats of VT with
a >100 msec increase in cycle length compared to baseline and no hemodynamic com-
promise) were then placed on IC + oral lB agent (5 with mexiletine, 2 with tocainide).
Similar effects on VT inducibility and cycle length were observed following the oral
combination. In conclusion, the addition of lidocaine to IC therapy produced favorable
effects on induced ventricular tachycardia in 58% of patients compared to IC agent
alone. Also, a positive PES response to lidocaine and IC therapy corresponded to
a similar positive response when either mexiletine or tocainide was substituted for
Iidocaine.
T he treatment of ventricular tachycardia is often
difficult and may not be adequately controlled
with a single antiarrhythmic agent. Reports in the
literature suggest combination of antiarrhythmic
agents, particularly class IA and lB agents (Vaughn
Williams classification), are effective in treatment of
ventricular arrhythmias)’2-3’4 However, there is only
limited data on the combination of lB (lidocaine) and
IC (encainide, flecainide) antiarrhythmic agents.’
The purpose of this paper is to report our experience
with this combination in 12 patients undergoing pro-
grammed electrical stimulation (PES) for the treat-
ment of symptomatic ventricular tachycardia.
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METHODS
Twelve patients with PES documented ventricular
tachycardia uncontrolled with single antiarrhyth-
mic agents were evaluated. The patient characteris-
tics are described in Table I. Specifically, these pa-
tients were selected for lidocaine plus encainide or
flecainide therapy based on previous PES response
to these drugs. They either had an increase in cycle
length of induced ventricular tachycardia following
encainide or flecainide alone or no previous adverse
outcome (decrease in ventricular tachycardia cycle
length) following lidocaine during PES.
The PES protocol employed by our group has been
described elsewhere.6 Briefly, the protocol involves
ventricular pacing at three different cycle lengths
(600, 500, and 400 msecs) with introduction of single,
double and triple extrastimulus until refractoriness.
This is followed by rapid ventricular pacing for five
captures up to a cycle length of 200 msec or 2:1
capture or until sustained ventricular tachycardia is
induced and reproducible. If ventricular tachycar-
dia is not induced at the right ventricular apex, the






Age (years) 61 ± 5
EF(%) 39± 16
Cardiac Diagnosis:





Out of Hospital VF 4
NSVT 3
SuVT = Sustained ventricular tachycardia; NSVT = Nonsustained ventricular
tachycardia; VF = Ventricular fibrillation;
tion were also assessed. The order of ascending dif-
ficulty in ventricular tachycardia induction were
one extrastimulus, two extrastimulus, three extra-
stimulus, and rapid ventricular pacing. For termina-
tion, ventricular pacing was considered less difficult
than external cardioversion to terminate ventricular
arrhythmias. Proarrhythmic response was consid-
ered as the induction of an arrhythmia using two
less extrastimuli B2 than previously required. In ad-
dition, the occurrence of sustained ventricular
tachycardia when only nonsustained ventricular
tachycardia was previously provoked and the in-
duction of sustained ventricular tachycardia at a
rate faster than previously induced were also con-
sidered as proarrhythmic responses.
DATA ANALYSIS
stimulation protocol is repeated at the right ventric-
ular outflow tract. Noninducible is defined as in-
duction of less than ten extra beats. Nonsustained
ventricular tachycardia is defined as induction of
greater than nine extra beats but less than 30 sec-
onds of ventricular tachycardia. Sustained ventricu-
lar tachycardia is defined as greater than 30 seconds
of ventricular tachycardia or early termination by
overdrive pacing or cardioversion because of hemo-
dynamic compromise. Following the combination
therapy, effective drug response is defined as less
than ten beats of nonsustained ventricular tachycar-
dia induced. A partial effective drug response is de-
fined as induction of 10 beats of nonsustained ven-
tricular tachycardia or sustained ventricular tachy-
cardia with significant lengthening of ventricular
tachycardia cycle length (>100 msecs) from baseline
and no hemodynamic compromise.
IC antiarrhythmic therapy consisted of either en-
cainide up to 150 mg/day or flecainide up to 500
mg/day or until adverse effects and/or excessive
lengthening of the QRS interval (>30%) were ob-
served. Lidocaine was administered as a 3 mg/kg
bolus over a 15-minute period followed by a 2 mg/
minute continuous infusion.
Electrocardiogram (EGG) measurements were ob-
tained by a trained research nurse who did not have
knowledge of this study. Measurement of EGG in-
tervals for all treatment groups were obtained from
the same EGG leads. Refractory periods were mea-
sured following the first extrastimulus. Supine blood
pressures were obtained with a blood pressure cuff
and sphygmomanometer.
In addition to the above measurements, the mode
of ventricular tachycardia induction and termina-
Data are presented as mean and standard deviation.
Differences between treatment groups were tested
by analysis of variance and Tukey’s Studentized
Range Test. A P < .05 was considered significant for
all tests.
RESULTS
Prior to combination therapy, all 12 patients had
induced sustained ventricular tachycardia at base-
line (no drug). Eleven out of 12 patients also had
induced sustained ventricular tachycardia while on
either encainide (N = 6) or flecainide (N = 5) alone.
One had nonsustained ventricular tachycardia with
encainide therapy. Nine out of 12 patients had in-
duced sustained ventricular tachycardia on lido-
caine alone. The other three patients either clini-
cally failed lidocaine therapy (N 2) or had a sus-
pected adverse reaction to lidocaine and were not
tested on lidocaine alone during PES.
In the nine patients who received lidocaine alone,
there were no significant differences in cycle length
compared to baseline (255 ± 30 vs 241 ± 32 ms). Also,
there were no significant changes in EGG intervals
or refractory periods compared to baseline. The
mean serum concentration of lidocaine was 2.8
± 0.7 mg/L.
The effects of IG agent alone are presented in
Tables II and III. Increases in sustained ventricular
tachycardia cycle length, blood pressure, and PR
and QRS intervals from baseline, but not refractory
period, were observed. The mean dose of IC agents
were 128 ± 34 mg/day for encainide and 280 ± 75
mg/day for flecainide. The serum concentration for
flecainide was 0.52 ± 0.31 mcg/ml. No patients dem-
onstrated a proarrhythmic response during IC ther-
apy compared to baseline.
* = Cycle length of induced sustained ventricular tachycardia.
f = P < 0.05 compared to baseline.
Two patients were not tested on lidocaine alone, one patient clinically failed
lidocaine and one patient had a suspected adverse reaction.
TABLE ill
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TABLE II
Cycle Length and Blood Pressure Response in
Patients With Sustained Ventricular Tachycardia






Baseline 257 ± 45 65 ± 38
Lidocaine (n = 7)1 260 ± 32 54 ± 37
IC 366±66t 93±38
IC + Lidocaine 394 ± 70t 107 ± 22
With the addition of lidocaine to encainide, two
patients became noninducible and one converted
from sustained to nonsustained ventricular tachy-
cardia (Table IV). No patients who received flecain-
ide therapy converted from sustained ventricular
tachycardia to nonsustained ventricular tachycardia
or became noninducible. Nine patients still had sus-
tained ventricular tachycardia but the mean cycle
length in seven increased 40 ± 25 msec, one had no
change in cycle length (flecainide therapy) and one
had a decrease in cycle length (encainide therapy)
with stable blood pressure (Table II). Overall, seven
out of 12 patients (4 encainide and 3 flecainide ther-
apy) were judged to be responders based on abolition
of sustained ventricular tachycardia or significant
increase in ventricular tachycardia cycle length and
stable blood pressure compared to baseline. The
dose of encainide, flecainide, and lidocaine used
during combination therapy remained the same or
similar as previous single drug therapy.
For patients with sustained ventricular tachycar-
dia the mode of induction with IC and lidocaine
therapy was the same in five patients, harder in two,
TABLE IV
ProgrammedElectrical Stimulation Response IC
plus Lidocaine Therapy
Baseline 12 Patients (SuVT)
IC 11 Patients (SuVT)
1 Patient (NSVT)
IC + Lidocaine 9 Patients (SuVT)
2 Patients (NI)
1 Patient (NSVT)
SuVT = Sustained ventricular tachycardia; NI = Noninducible; NSVT = Non-
sustained ventricular tachycardia.
and easier in two compared to IG therapy alone. The
mode of arrhythmia termination (either by cardio-
version or rapid ventricular pacing) was the same in
eight patients and harder in one when compared to
IC agents alone. One patient required cardioversion
secondary to accelerated ventricular tachycardia
after attempted termination by rapid ventricular
pacing. However, no patients were considered to
have a proarrhythmic response.
Seven patients who were judged to be effective or
partial responders to combination of either encain-
ide or flecainide and lidocaine were continued on
their respective IC agent along with an oral lB agent
(mexiletine n = 5, tocainide n = 2). Following oral
combination therapy similar PES responses were
observed (Tables V and VI). The mode of induction
and termination were also similar. The mean dose of
encainide, flecainide, mexiletine and tocainide were
131 ± 38 mg/day, 316 ± 160 mg/day, 630 ± 147
mg/day, and 1500 ± 300 mg/day, respectively. The
serum concentrations for flecainide, mexiletine and
tocainide were 0.56 ± 0.13 mcg/ml, 0.7 ± 0.4 mcg/
ml, and 5.2 ± 0.7 mcg/ml, respectively. Overall, five
out of seven patients were discharged on combina-
tion therapy. The two patients who were not dis-
charged on combination therapy required discon-
Change in Refractory Period and ECG Intervals
RP* PR(ms) QRS(ms) QTc(ms)
Baseline 246 ± 23 .19 ± .04 .11 ± .02 .43 ± .04
IC 265 ± 23 .23 ± .04f .13 ± .02f .47 ± .06
IC + Lidocaine 265 ± 25 .23 ± .05t .14 ± .02t .45 ± .04
= Refractory period of first extrastimulus. t = P < 0.05 compared to baseline.
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TABLE V
Sustained Ventricular Tachycardia Cycle Length and
Blood Pressure Response to IB, IC, IC + lB. and IC
+ oral lB Antiarrhythmic Agents (n = 4)
Systolic Pressure
Treatment Cycle Length* (ms) (mmHg)
Baseline 247 ± 22 52 ± 44
Lidocaine 259 ± 8 73 ± 40
IC 348±37t 114±37
IC + Lidocaine 388 ± 33t 121 ± 34
lC+OraIIB 41O±40f 122±17
* = Cycle length of induced sustained ventricular tachycardia.
t = P < 0.05 compared to baseline.
tinuation of their therapy secondary to adverse ef-
fects (rash, and GNS disturbances).
DISCUSSION
Our present study indicates that the addition of li-
docaine to either encainide or flecainide can en-
hance antiarrhythmic response. Overall, seven out
of 12 patients were judged to have a favorable re-
sponse, i.e., effective or partially effective to the
combination therapy. This high success rate can be
attributed to the definition of favorable response,
which include those who had a significant increase
in ventricular tachycardia cycle length with no
symptoms. Waller et al., showed that patients who
had an increase in ventricular tachycardia cycle
length of greater than 100 msec and no severe
symptoms had a long-term outcome similar to pa-
tients who were noninducible.7 If a stricter criteria,
noninducibility, was used to define favorable re-
sponse, the response rate from our combination
therapy would be much lower (2/12 patients re-
sponding). This low response rate is similar to a pre-
vious report by Ross et al., who showed that oral
encainide plus lidocaine produced no increase in
efficacy compared to baseline when noninducibility
was used as an endpoint.’
Our experience also indicates that a favorable re-
sponse to combination of lidocaine and IC agents
predicts a similar response to combination of oral lB
and IC agents. This supports a previous study by
Podrid and Lown who showed that lidocaine is pre-
dictive of tocainide’s response in 78% of patients.8 It
should be pointed out that in our study, only posi-
tive responses were evaluated. No information is
available about negative concordance between lido-
caine and oral lB drugs in our patient population.
Although proarrhythmic response to IC therapy
has been reported to occur none were seen during
our study.92 This is due to our patient selection
which excluded patients that did not have a favor-
able response to IC therapy. Further, no proarrhyth-
mic responses were seen with the addition of lido-
caine to IG therapy. This was also demonstrated in
previous studies.1314 Other studies have shown that
lidocaine may prevent and/or treat proarrhythmic
responses to flecainide.14’1’ Thus, the addition of li-
docaine to IG therapy appears to be safe and may
prevent proarrhythmic responses in addition to en-
hancing therapeutic effects.13’14 However, further
data is needed to substantiate this.
A potential concern with the results of our study is
the general grouping of lB and IC antiarrhythmic
agents, with the assumption that all lB or IC agents
produce similar results. Previous studies showed
that neither mexiletine nor tocainide predicts re-
sponse to each other.16 However, within the IC
group. we observed similar response to encainide
and flecainide with or without lidocaine combina-
tion. The ventricular tachycardia cycle length post
encainide and flecainide increased 127 ± 37 msec
and 123 ± 90 msec from baseline, respectively. With
the addition of lidocaine, the ventricular tachycar-
dia cycle length post lidocaine-encainide and lido-
caine-flecainide increased 151 ± 79 msec and 141
± 83 msec from baseline respectively. Unfortu-
nately, due to the low number of patients, no com-
parisons can be made on oral lB and IC combination
therapy.
In summary, our small series of patients showed
that the addition of lidocaine to either flecainide or
encainide improved therapeutic response when
TABLE Vt
Programmed Electrical Stimulation Response: IC vs
IC + Lidocaine vs IC + Oral lB Therapy
Baseline 7 Patients (SuVT)
IC 6 Patients (SuVT)
1 Patient (NSVT)
IC + Lidocaine 4 Patients (SuVT)
2 Patients (NI)
1 Patient (NSVT)
IC + Oral lB 4 Patients (SuVT)
2 Patients (NI)
1 Patient (NSVT)
SuVT = Sustained ventricular tachycardia; NI = Noninducible; NSVT = Non-
sustained ventricular tachycardia.
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modification of sustained ventricular tachycardia is
used as an endpoint. Furthermore, a favorable re-
sponse observed with a combination of lidocaine
and flecainide or encainide predicted a similar re-
sponse to a combination of oral LB (mexiletine or
tocainide) and IC (flecainide or encainide) agents.
Therefore, TB and IC combination therapy may be a
viable alternative for patients refractory to single an-
tiarrhythmic agents. Further studies, however, are
needed to verify our favorable results for LB and IC
combination therapy.
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